Hovnanian Enterprises, Inc. (HOV) Reaches $2.10 After 3.00% Down Move; Shorts at Viking Therapeutics (VKTX) Raised By 9.79%

February 15, 2018 - By Peter Mason

Viking Therapeutics Incorporated (NASDAQ:VKTX) had an increase of 9.79% in short interest. VKTX’s SI was 1.61 million shares in February as released by FINRA. Its up 9.79% from 1.47M shares previously. With 477,300 avg volume, 3 days are for Viking Therapeutics Incorporated (NASDAQ:VKTX)’s short sellers to cover VKTX’s short positions. The SI to Viking Therapeutics Incorporated’s float is 10.16%. The stock increased 2.08% or $0.128 during the last trading session, reaching $6.298. About 726,753 shares traded. Viking Therapeutics, Inc. (NASDAQ:VKTX) has risen 5.04% since February 15, 2017 and is uptrending. It has underperformed by 11.66% the S&P500.

The stock of Hovnanian Enterprises, Inc. (NYSE:HOV) is a huge mover today! The stock decreased 1.87% or $0.04 during the last trading session, reaching $2.1. About 722,602 shares traded. Hovnanian Enterprises, Inc. (NYSE:HOV) has risen 51.90% since February 15, 2017 and is uptrending. It has outperformed by 35.20% the S&P500.The move comes after 7 months negative chart setup for the $278.55M company. It was reported on Feb, 15 by Barchart.com. We have $2.04 PT which if reached, will make NYSE:HOV worth $8.36 million less.

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapies for metabolic and endocrine disorders. The company has market cap of $296.31 million. The Company’s lead clinical program is VK5211, an orally available drug candidate, which is in a phase II clinical trials for acute rehabilitation following non-elective hip fracture surgery. It currently has negative earnings. The firm also develops VK2809, an orally available, tissue, and receptor-subtype selective agonist of the thyroid beta receptor for the treatment of hypercholesterolemia and fatty liver disease, as well as for the orphan indication glycogen storage disease type Ia; and VK0214 for the treatment of orphan indication X-linked adrenoleukodystrophy, a rare X-linked, inherited neurological disorder.

Among 4 analysts covering Viking Therapeutics (NASDAQ:VKTX), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Viking Therapeutics had 11 analyst reports since April 7, 2016 according to SRatingsIntel. The firm earned “Buy” rating on Wednesday, November 29 by Roth Capital. H.C. Wainwright maintained the shares of VKTX in report on Thursday, August 10 with “Buy” rating. The rating was maintained by Maxim Group on Wednesday, July 12 with “Buy”. The company was maintained on Thursday, August 11 by Laidlaw. The stock has “Buy” rating by H.C. Wainwright on Friday, November 10. The firm has “Buy” rating by Maxim Group given on Tuesday, May 24. H.C. Wainwright maintained it with “Buy” rating and $700 target in Monday, July 17 report. The stock of Viking Therapeutics, Inc. (NASDAQ:VKTX) has “Buy” rating given on Tuesday, June 6 by Maxim Group. The firm earned “Buy” rating on Thursday, August 10 by Maxim Group. H.C. Wainwright initiated Viking Therapeutics, Inc. (NASDAQ:VKTX) rating on Thursday, April 7. H.C. Wainwright has “Buy” rating and $6 target.

Among 2 analysts covering Hovnanian (NYSE:HOV), 0 have Buy rating, 2 Sell and 0 Hold. Therefore 0 are positive. Hovnanian had 4 analyst reports since September 10, 2015 according to SRatingsIntel. On Thursday, January 12 the stock rating was downgraded by JMP Securities to “Mkt Underperform”. M Partners maintained the shares of HOV in report on Thursday, September 10 with “Neutral” rating. As per Friday, June 3, the company rating was maintained by M Partners. On Friday, December 22 the stock rating was downgraded by M Partners to “Sell”.

Investors sentiment decreased to 0.98 in 2017 Q3. Its down 0.02, from 1 in 2017Q2. It dived, as 9 investors sold Hovnanian Enterprises, Inc. shares while 33 reduced holdings. 18 funds opened positions while 23 raised stakes. 46.83 million shares or 4.40% more from 44.86 million shares in 2017Q2 were reported. Swiss Retail Bank reported 0% of its portfolio in Hovnanian Enterprises, Inc. (NYSE:HOV). 2,867 were accumulated by Barclays Public Ltd Liability. Her Majesty The Queen In Right Of The Province Of Alberta As Represented By Alberta Investment Mngmt invested 0% of its portfolio in Hovnanian Enterprises, Inc. (NYSE:HOV). First Trust Advsrs L P owns 99,145 shares. Legal General Gru Public Ltd Co invested 0% of its portfolio in Hovnanian Enterprises, Inc. (NYSE:HOV). Aperio Grp Inc Ltd Limited Liability Company has 0% invested in Hovnanian Enterprises, Inc. (NYSE:HOV). Manufacturers Life The reported 104,079 shares stake. Ellington Grp Incorporated Ltd Liability Corporation reported 483,467 shares. Jefferies Ltd Liability Com has 38,571 shares. Stifel Fincl stated it has 0% of its portfolio in Hovnanian Enterprises, Inc. (NYSE:HOV). Bridgeway Inc invested 0% in Hovnanian Enterprises, Inc. (NYSE:HOV). Accuvest Global Advsr holds 0.03% or 18,180 shares in its portfolio. Bnp Paribas Arbitrage stated it has 0% of its portfolio in Hovnanian Enterprises, Inc. (NYSE:HOV). Natixis has 15,354 shares for 0% of their portfolio. Citadel Advsrs Limited Company stated it has 643,358 shares.

Hovnanian Enterprises, Inc. designs, constructs, markets, and sells residential homes in the United States. The company has market cap of $278.55 million. It constructs single-family detached homes, attached townhomes and condominiums, urban infill, and active lifestyle homes. It currently has negative earnings. The firm markets its build homes for first-time buyers, first-time and second-time move-up buyers, luxury buyers, active lifestyle buyers, and empty nesters in 167 communities in 33 markets.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Peter Mason

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: